Literature DB >> 773949

Glucagon metabolism in man, studies on the metabolic clearance rate and the plasma acute disappearance time of glucagon in normal and diabetic subjects.

F P Alford, S R Bloom, J D Nabarro.   

Abstract

To investigate further the "hyperglucagonaemia" of diabetes mellitus, the metabolic clearance rate (MCR) and acute disappearance time (t1/2) of unlabelled pancreatic glucagon were estimated in 9 normal subjects and 7 insulin-dependent diabetics, using a constant infusion technique. The mean MCR (+/-SE) was similar for both groups (control: 9.0 +/- 0.6; diabetics: 11.4 +/- 1.0 ml/kg/min). The MCR was not influenced by the concentration of glucagon at the time of plateau, and the exogenous hormone appeared to be handled similarly to endogenous glucagon. On the other hand, t1/2 calculated from the fractional decay rate of glucagon from plateau was significantly prolonged in the diabetics (t1/2 6.6 +/- 0.5 min) compared with the control group (t1/2 4.8 +/- 0.2 min, P less than 0.01). Furthermore, there was no correlation between MCR and t1/2, for the control, diabetic, or combined group. It therefore appears that the MCR of glucagon is similar in normal and diabetic subjects. However, since the acute disappearance time (t1/2) of glucagon is not identical in these two groups, it appears that the kinetics of the overall in vivo metabolism of pancreatic glucagon are not similar in diabetic and control subjects.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 773949     DOI: 10.1210/jcem-42-5-830

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  16 in total

1.  Postprandial mesenteric blood flow.

Authors:  G D Braatvedt; A E Read; R J Corrall; M Halliwell; P N Wells
Journal:  Gut       Date:  1991-11       Impact factor: 23.059

2.  Pharmacokinetics modeling of exogenous glucagon in type 1 diabetes mellitus patients.

Authors:  Dayu Lv; Marc D Breton; Leon S Farhy
Journal:  Diabetes Technol Ther       Date:  2013-08-26       Impact factor: 6.118

Review 3.  Intranasal drug delivery. Potential advantages and limitations from a clinical pharmacokinetic perspective.

Authors:  A E Pontiroli; A Calderara; G Pozza
Journal:  Clin Pharmacokinet       Date:  1989-11       Impact factor: 6.447

4.  Pharmacokinetics of insulin aspart and glucagon in type 1 diabetes during closed-loop operation.

Authors:  Ahmad Haidar; Claire Duval; Laurent Legault; Rémi Rabasa-Lhoret
Journal:  J Diabetes Sci Technol       Date:  2013-11-01

5.  Hyperalaninaemia is an early feature of diabetes secondary to total pancreatectomy.

Authors:  S Del Prato; S Vigili de Kreutzenberg; R Trevisan; E Duner; A Avogaro; R Nosadini; U Baccaglini; C Tremolada; A Tiengo
Journal:  Diabetologia       Date:  1985-05       Impact factor: 10.122

6.  Effect of portasystemic venous shunt surgery on hyperglucagonaemia in cirrhosis: paired studies of pre- and post-shunted subjects.

Authors:  F J Dudley; F P Alford; D J Chisholm; D M Findlay
Journal:  Gut       Date:  1979-10       Impact factor: 23.059

7.  Glucagon sensitivity and clearance in type 1 diabetes: insights from in vivo and in silico experiments.

Authors:  Ling Hinshaw; Ashwini Mallad; Chiara Dalla Man; Rita Basu; Claudio Cobelli; Rickey E Carter; Yogish C Kudva; Ananda Basu
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-07-07       Impact factor: 4.310

8.  Extrapancreatic glucagon and glucagonlike immunoreactivity in depancreatized dogs. A quantitative assessment of secretion rates and anatomical delineation of sources.

Authors:  W A Muller; L Girardier; J Seydoux; M Berger; A E Renold; M Vranic
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

9.  Kinetics of human connecting peptide in normal and diabetic subjects.

Authors:  O K Faber; C Hagen; C Binder; J Markussen; V K Naithani; P M Blix; H Kuzuya; D L Horwitz; A H Rubenstein; N Rossing
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

10.  Glucagon levels in normal and diabetic subjects: use of a specific immunoabsorbent for glucagon radioimmunoassay.

Authors:  F P Alford; S R Bloodm; J D Nabarro
Journal:  Diabetologia       Date:  1977-01       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.